RVMD · Revolution Medicines, Inc. · Executive Compensation

$206.64 +0.75 (+0.36%) At close · Oct 2

Russell 1000 member Rebalance outlook locked

Market Cap

$43.93B

214.34M

Volume · Oct 2 1.57M Avg daily vol (3M) 1.91M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Mark Goldsmith	M.D., Ph.D. President and Chief Executive Officer	$812,500	—	$3,968,076	$8,995,114	$889,700	$7,000	$14,672,390
Stephen Kelsey	M.D., FRCP, FRCPath President, Research and Development	$625,833	—	$1,491,084	$3,378,112	$461,200	$7,000	$5,963,229
Margaret Horn	Chief Operating Officer	$582,666	—	$1,165,164	$2,639,727	$426,500	$7,000	$4,821,057
Jeffrey Cislini	General Counsel and Secretary	$523,750	—	$896,280	$2,030,559	$261,000	$7,000	$3,718,589
Jack Anders	Chief Financial Officer	$523,333	—	$831,096	$1,882,882	$343,800	$7,000	$3,588,111

Fiscal 2024

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Mark Goldsmith	M.D., Ph.D. President and Chief Executive Officer	$689,167	—	$2,682,000	$6,049,524	$651,800	$7,000	$10,079,491
Steve Kelsey	M.D., FRCP, FRCPath President, Research and Development	$573,333	—	$1,531,720	$3,465,953	$371,600	$7,000	$5,949,607
Stephen Kelsey	M.D., FRCP, FRCPath President, Research and Development	$573,333	—	$1,531,720	$3,465,953	$371,600	$7,000	$5,949,607
Margaret Horn	Chief Operating Officer	$540,833	—	$1,221,800	$2,764,671	$350,100	$7,000	$4,884,404
Jack Anders	Chief Financial Officer	$473,333	—	$786,720	$1,780,178	$245,300	$7,000	$3,292,532
Xiaolin Wang	—	$455,500	—	$721,160	$1,631,830	$238,700	$7,000	$3,054,190
Jeffrey Cislini	General Counsel and Secretary	$477,166	—	$625,800	$1,416,051	$217,200	$7,000	$2,743,217

Fiscal 2023

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Mark Goldsmith	M.D., Ph.D. President and Chief Executive Officer	$631,121	—	$2,756,000	$6,540,026	$477,100	$7,000	$10,411,247
Stephen Kelsey	M.D., FRCP, FRCPath President, Research and Development	$512,575	—	$1,060,000	$2,522,324	$292,600	$7,000	$4,394,499
Steve Kelsey	M.D., FRCP, FRCPath President, Research and Development	$512,575	—	$1,060,000	$2,522,324	$292,600	$7,000	$4,394,499
Margaret Horn	Chief Operating Officer	$512,575	—	$1,060,000	$2,522,324	$291,500	$7,000	$4,393,399
Xiaolin Wang	—	$415,737	—	$768,500	$1,828,685	$211,000	$7,000	$3,230,922
Jack Anders	Chief Financial Officer	$438,384	—	$704,900	$1,677,345	$219,900	$7,000	$3,047,529
Jeffrey Cislini	General Counsel and Secretary	$405,000	—	$588,300	$1,399,890	$178,600	$7,000	$2,578,790

Fiscal 2022

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Mark Goldsmith	M.D., Ph.D. President and Chief Executive Officer	$606,667	—	$1,930,240	$4,234,032	$439,900	$7,000	$7,217,839
Steve Kelsey	M.D., FRCP, FRCPath President, Research and Development	$497,500	—	$720,128	$1,583,971	$274,500	$7,000	$3,083,099
Margaret Horn	Chief Operating Officer	$497,500	—	$720,128	$1,583,971	$271,100	$7,000	$3,079,699
Jack Anders	Chief Financial Officer	$371,000	—	$431,396	$971,265	$166,800	$7,000	$1,947,461
Xiaolin Wang Sc.D	Executive Vice President and Clinical Development	$400,000	—	$371,200	$816,480	$197,100	$7,000	$1,791,780
Xiaolin Wang	—	$400,000	—	$371,200	$816,480	$197,100	$7,000	$1,791,780

Fiscal 2021

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Mark Goldsmith	M.D., Ph.D. President and Chief Executive Officer	$580,833	—	$2,037,600	$4,785,184	$418,300	$7,000	$7,828,917
Margaret Horn	Chief Operating Officer	$482,333	—	$636,750	$1,486,522	$283,700	$7,000	$2,896,305
Steve Kelsey	M.D., FRCP, FRCPath President, Research and Development	$482,333	—	$636,750	$1,486,522	$283,700	$7,000	$2,896,305
Xiaolin Wang	—	$377,833	—	$475,440	$1,109,936	$197,600	$7,000	$2,167,809
Xiaolin Wang Sc.D	Executive Vice President and Clinical Development	$377,833	—	$475,440	$1,109,936	$197,600	$7,000	$2,167,809
Jack Anders	Chief Financial Officer	$311,333	—	$314,130	$733,351	$143,800	$7,000	$1,509,614

Fiscal 2020

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Mark Goldsmith	M.D., Ph.D. President and Chief Executive Officer	$554,011	—	—	$1,426,200	$406,000	$2,000	$2,388,211
Steve Kelsey	President, Research and Development	$464,210	—	—	$522,559	$273,700	$2,000	$1,262,469
Margaret Horn	Chief Operating Officer	$459,691	—	—	$522,559	$273,700	$2,000	$1,257,950

Fiscal 2019

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Mark Goldsmith	M.D., Ph.D. President and Chief Executive Officer	$504,300	—	—	$3,808,974	$260,980	$2,000	$4,576,254
Chief Operating Officerand General Counsel	—	$384,375	—	—	$1,662,587	$166,150	$2,000	$2,215,112
Margaret Horn	Chief Operating Officer and General Counsel	$384,375	—	—	$1,662,587	$166,150	$2,000	$2,215,112
Steve Kelsey	President, Research and Development	$424,350	—	—	$1,298,253	$170,800	$2,000	$1,895,403

Executive changes

Person	Role	Change	Effective	Filed
Steve Kelsey, M.D., FRCP, FRCPath	employment with the Company	Retired	2027-01-04	2026-06-22
Steve Kelsey, M.D., FRCP, FRCPath	senior advisor to the chief executive officer	Appointed	2026-07-01	2026-06-22
Barbara Weber, M.D.	director, member of the Board’s Nominating and Corporate Governance Committee and member of the Board’s Research & Development C	Resigned	2025-06-26	2025-06-18
Frank K. Clyburn, Jr.	Class II director	Appointed	2024-08-05	2024-08-07
Sandra J. Horning, M.D.	member of the Board	Appointed	2023-11-09	2023-11-09
Lorence Kim, M.D.	Chair of the Audit Committee	Appointed	—	2023-09-05
Alexis Borisy	member of the Audit Committee	Appointed	—	2023-09-05
Eric T. Schmidt, Ph.D.	Board of Directors	Resigned	2023-09-05	2023-09-05
Jack Anders	Chief Financial Officer	Appointed	2022-09-01	2022-09-01
Neil Exter	the Board	Resigned	2022-07-12	2022-07-13
Lorence Kim, M.D.	member of the Board	Appointed	2022-07-12	2022-07-13

Key facts CIK 1628171 CUSIP 76155X100 13F (30d) 20 filings 17 filers Visit website Investor relations